Magenta therapeutics announces data presentations related to its mobilization and conditioning programs at the 2021 american society of hematology (ash) annual meeting

Cambridge, mass.--(business wire)--magenta therapeutics (nasdaq: mgta), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced positive top-line results from an investigator-initiated phase 2 clinical trial of mgta-145 stem cell mobilization in multiple myeloma. the data were accepted for a poster presentation at the 2021 american society of hematology (ash) annual meeting, to be held in a
DNTH Ratings Summary
DNTH Quant Ranking